Citadel Advisors
KROS icon

Citadel Advisors’s Keros Therapeutics KROS Stock Holding History

Citadel Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,200
Closed -$190K – 14343
2026
Q1 		$190K Sell
17,200
-5,000
-23% -$77.2K ﹤0.01% 11464
2025
Q4 		$452K Buy
22,200
+300
+1% +$5.26K ﹤0.01% 9276
2025
Q3 		$346K Sell
21,900
-14,100
-39% -$208K ﹤0.01% 10019
2025
Q2 		$481K Sell
36,000
-129,100
-78% -$1.74M ﹤0.01% 8726
2025
Q1 		$1.68M Buy
165,100
+151,100
+1,079% +$1.75M ﹤0.01% 5879
2024
Q4 		$222K Buy
14,000
+2,700
+24% +$140K ﹤0.01% 10262
2024
Q3 		$656K Buy
11,300
+10,100
+842% +$499K ﹤0.01% 7683
2024
Q2 		$54.8K Sell
1,200
-11,100
-90% -$596K ﹤0.01% 11656
2024
Q1 		$814K Buy
12,300
+10,800
+720% +$640K ﹤0.01% 7368
2023
Q4 		$59.6K Buy
1,500
+900
+150% +$28.2K ﹤0.01% 11598
2023
Q3 		$19.1K Hold
600
– – ﹤0.01% 12661
2023
Q2 		$24.1K Sell
600
-400
-40% -$17.5K ﹤0.01% 12567
2023
Q1 		$42.7K Sell
1,000
-17,400
-95% -$879K ﹤0.01% 12365
2022
Q4 		$884K Sell
18,400
-7,400
-29% -$346K ﹤0.01% 7043
2022
Q3 		$971K Buy
25,800
+8,300
+47% +$288K ﹤0.01% 7055
2022
Q2 		$484K Buy
17,500
+10,400
+146% +$456K ﹤0.01% 8730
2022
Q1 		$386K Sell
7,100
-19,100
-73% -$980K ﹤0.01% 10000
2021
Q4 		$1.53M Buy
+26,200
New +$1.31M ﹤0.01% 6843

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Citadel Advisors's KROS Position: Q2 2026 in Review

Citadel Advisors reduced its Keros Therapeutics (KROS) stake by 2.6% in Q2 2026, selling an estimated $118K and leaving 396,098 shares worth $4.24M. The position accounts for ﹤0.01% of the portfolio, ranked #5019.

Citadel Advisors first reported a position in KROS in Q2 2020 and has held it in 24 quarters since. The position peaked at $40.9M in Q3 2024. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Citadel Advisors held 396,098 shares of Keros Therapeutics worth $4.24M as of Q2 2026.
  • Citadel Advisors sold 10,568 Keros Therapeutics shares in Q2 2026, an estimated $118K.
  • Keros Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5019 holding.
  • Citadel Advisors first reported a position in Keros Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • Citadel Advisors's Keros Therapeutics position peaked at $40.9M in Q3 2024.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.